Drug Pricing: Page 8
-
Alex Wong via Getty Images
Biden pushes forward on Medicare price negotiation
But opposition from the drug industry and congressional Republicans could make the Democrats' signature proposal an uphill battle.
By Jonathan Gardner • Sept. 10, 2021 -
Coherus, known for biosimilars, nears an immunotherapy battle with big pharma
New lung cancer results could make Coherus the next entrant in an ultra-competitive market dominated by pricey drugs like Merck's Keytruda.
By Ben Fidler • Aug. 19, 2021 -
Explore the Trendline➔
Elizabeth Regan/BioPharma Dive
TrendlineDrug pricing
President Trump’s efforts to install a most-favored nation pricing policy present new risks for an industry already adjusting to Medicare price negotiations.
By BioPharma Dive staff -
Alex Wong via Getty Images
Biden embraces Medicare drug price negotiation as Democrats seek to widen health coverage
In a speech Thursday afternoon outlining his proposal, which features several familiar policy ideas, Biden emphasized price negotiation, but allowing for drugmaker profit.
By Jonathan Gardner • Updated Aug. 12, 2021 -
Permission granted by Biogen
VA leaves Aduhelm off coverage list, recommending against controversial Alzheimer's drug
The decision, which does provide for certain exceptions, is another bump in what's become a rocky market rollout for Biogen's medicine.
By Ned Pagliarulo • Updated Aug. 12, 2021 -
Startup EQRx to take drug price mission public through $1.8B SPAC deal
A merger with a blank-check company backed by Casdin Capital will greatly expand the resources available to EQRx, which aims to develop competitors to existing drugs and sell them at "radically lower" prices.
By Ned Pagliarulo • Aug. 6, 2021 -
Permission granted by Biogen
Questions on new Alzheimer's drug benefit, price loom large at ICER meeting
"Right now, and I think for a while, the access is going to be pretty limited," former CMS and FDA head Mark McClellan said at the meeting, which featured yet another rebuke by experts of Aduhelm.
By Ned Pagliarulo • July 16, 2021 -
Permission granted by Biogen
Medicare to weigh nationwide coverage rules for Biogen Alzheimer's drug
CMS will consider whether to set a single policy for Aduhelm, a process that could shape how millions of Americans access the controversial treatment.
By Ned Pagliarulo • Updated July 13, 2021 -
Permission granted by Biogen
Alzheimer's Association, insurers press Medicare for coverage rules on Aduhelm
Days after the FDA narrowed the target population for Biogen's drug, the patient advocacy group said it's urging Medicare to adopt a nationwide policy. Payers are seeking guidance, too.
By Jonathan Gardner • Updated July 12, 2021 -
Permission granted by Biogen
ICER stands by view on Biogen's Aduhelm, says sharp price cut needed
The influential nonprofit maintains that the clinical trial evidence supporting Aduhelm is insufficient to prove a health benefit. But if some efficacy is assumed, ICER argues Biogen's $56,000 price tag is far too high.
By Ned Pagliarulo • June 30, 2021 -
Permission granted by Biogen
Congress pressures FDA and Biogen on Alzheimer's drug approval, price
The agency's decision-making process as well as Biogen's pricing of Aduhelm at $56,000 per year are both under the microscope as the repercussions of the controversial OK continue to be felt.
By Jonathan Gardner • June 28, 2021 -
As 5 Blue Cross Blue Shield plans join to tackle drug prices, some remain skeptical
Another healthcare venture promises to lower costs, this time by using patient data on drug efficacy through a handful of large insurers.
By Samantha Liss • June 23, 2021 -
Novo keeps price in line with FDA approval of second obesity shot
Wegovy, a weekly drug, joins daily Saxenda in the pharma's portfolio, which could soon be under pressure from an experimental Lilly medicine.
By Jonathan Gardner • June 7, 2021 -
Brooks-LaSure confirmed by Senate as CMS head
While CMS now has an administrator in place, President Biden still hasn't nominated anyone to run the FDA more than four months after taking office.
By Rebecca Pifer Parduhn • May 25, 2021 -
ICER, vocal critic of drug company pricing, turns scrutiny to insurers
The watchdog group plans to examine how cost sharing can hurt access to care, but it won't assess some of the most controversial insurer practices.
By Jonathan Gardner • May 25, 2021 -
Win McNamee via Getty Images
Humira patents take center stage as House panel targets AbbVie pricing
CEO Richard Gonzalez defended the company's practices, arguing its profits help spur innovation: "The products that are on the market today pay for the products of the future," he said.
By Jonathan Gardner • May 18, 2021 -
Novartis challenge to Amgen's Enbrel patents ends at Supreme Court's door
The top court declined to hear Novartis' appeal of an earlier federal ruling in Amgen's favor, likely preventing biosimilar competition until 2029.
By Ned Pagliarulo • May 18, 2021 -
Eli Lilly challenges HHS order to repay hospitals for 340B violations
The drugmaker filed a lawsuit in district court to stop government efforts to force compliance with new conditions for the drug discount program by June 1.
By Hailey Mensik , Rebecca Pifer Parduhn • Updated May 21, 2021 -
Permission granted by Biogen
ICER, unconvinced by Biogen data, suggests low price for Alzheimer's drug
The influential watchdog group found the evidence supporting aducanumab "insufficient" and suggested the drug would be cost effective at up to $8,300 per year, well short of what some analysts are predicting.
By Ned Pagliarulo • May 5, 2021 -
Sean Gallup via Getty Images
Pfizer forecasts $26B in coronavirus vaccine revenue this year
The sum is $11 billion higher than Pfizer had estimated in February and, if realized, would make the vaccine the highest grossing pharmaceutical product by revenue in a single year.
By Ned Pagliarulo • May 4, 2021 -
Courtesy of Bristol Myers Squibb
New CAR-T therapy from Bristol, Bluebird effective but too costly, ICER finds
The influential drug cost watchdog recommended a discount of between 37% and 54% to the $419,500 list price the companies charge for Abecma, a multiple myeloma cell therapy cleared by the FDA in March.
By Ned Pagliarulo • Updated April 6, 2021 -
Retrieved from C-SPAN on February 24, 2021
Becerra confirmed as HHS secretary
The 50-49 vote in the Senate was almost entirely along party lines. The only Republican to cross the aisle was Sen. Susan Collins of Maine.
By Shannon Muchmore • March 18, 2021 -
Alex Wong via Getty Images
The top drugs that could be impacted by an obscure provision in the pandemic relief law
Elimination of the so-called penny rule in Medicaid could force drugmakers to pay larger rebates on a number of top medicines, including some HIV, diabetes and anti-inflammatory drugs.
By Jonathan Gardner • March 12, 2021 -
Countering payers, drugmakers say net prices declined in 2020
Reports from three large pharmaceutical companies indicate increasing rebate payments and discounts to insurers more than offset the average price increases they took on their medicines.
By Jonathan Gardner • March 5, 2021 -
Retrieved from C-SPAN on February 23, 2021
HHS nominee Becerra backs price transparency, hospital competition at first Senate hearing
President Joe Biden's pick for HHS chief will testify Wednesday in front of the finance committee, which will vote on sending the nomination to the full Senate.
By Shannon Muchmore • Feb. 24, 2021 -
As COVID-19 becomes a business, vaccine makers confront thorny pricing questions
Yearly vaccinations could be required after the pandemic ebbs. Will drugmakers change how they approach pricing their shots?
By Jonathan Gardner • Feb. 9, 2021
Previous
